CETP Inhibitors: Should We Continue to Pursue This Pathway?

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Metabolic Disease

Background:

• Cholesteryl ester transfer protein (CETP) inhibitors have been investigated for over 20 years.
• Their primary mechanism involves increasing high-density lipoprotein cholesterol (HDL-C) levels.
• Interest stems from the potential to prevent cardiovascular disease.

Purpose of the Study:

• To review and integrate existing clinical trial data on CETP inhibitors.
• To explore the potential for CETP inhibitors in cardiovascular disease prevention.
• To assess emerging data and future development pathways.

Main Methods:

• Review of prior clinical trial data.
• Integration of emerging research findings.
• Analysis of recent observations and their implications.

Main Results:

• Previous large trials failed to reduce cardiovascular events.
• One program showed cardiovascular risk reduction but was halted due to adipose tissue accumulation.
• Recent findings suggest CETP inhibition may prevent cardiovascular events via lipid lowering and benefit glycemic control in diabetes.

Conclusions:

• CETP inhibitors may offer a protective effect against both cardiovascular disease and diabetes.
• Revised strategies for clinical development are needed.
• There is potential for CETP inhibitors in preventive cardiology.